Exelixis extends research collaboration with Bristol-Myers Squibb |
|
|
|
Published
:
Fri, 21 Sep 2007 11:22
|
LONDON (Thomson Financial) - Exelixis Inc said that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to develop and commercialise novel therapies targeted against the Liver X Receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.The collaboration, originally established in January of 2005 for a period of two years, has been extended at Bristol-Myers Squibb's request through to January 2009.Bristol-Myers Squibb also has retained the option to further extend the research collaboration by an additional year. Terms of the extension include additional research funding of 7.5 mln usd.tf.TFN-Europe_newsdesk@thomson.comrwCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Exelixis 2Q loss widens on costs 